Search PubMed⌕ Search

PubMed · 2258306

Cholesterol analyzers.

Abstract

We evaluated eight cholesterol analyzers from eight manufacturers, basing our ratings on the accuracy of the cholesterol results (from both fingerstick and venous samples) compared with the national reference method for cholesterol; repeatability (precision) of the cholesterol results; human factors design; suitability for off-site testing; sample analysis time and throughput; and the effects of sample interferences and electrical disturbances on cholesterol test results. Although many of the units perform additional tests, we did not evaluate performance for these tests; our ratings are based solely on the cholesterol tests performed in this evaluation. We rated seven units Acceptable. We rated one unit Unacceptable because it provided inaccurate and imprecise cholesterol results; also, its reagent system has inherent problems that contribute to human error and, thus, erroneous results. The manufacturer is no longer marketing this unit but is supporting the reagents. We found advantages and disadvantages for each Acceptable unit. To help users choose the appropriate unit for specific applications, we developed a Selection Factors table based on features and applications; this table is presented in the Discussion section. We recommend that all of these units be operated by qualified personnel to minimize the potential for human error. [See "Improved Regulations for Clinical Laboratory Tests."] For further discussion of related issues, see the Clinical Perspective, "Cardiovascular Disease: Reducing the Risk through Cholesterol Screening"; "Cholesterol Readers"; and "The Discontinued Johnson & Johnson CLA 200" in this issue.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1990. Cholesterol analyzers.. https://pubmed.ncbi.nlm.nih.gov/2258306/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.

Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) is the precursor of Delta9-tetrahydrocannabinol (Delta9-THC) in hemp plants. During smoking, the non-psychoactive Delta9-THCA-A is converted to Delta9-THC, the main psychoactive component of marihuana and hashish. Although the decarboxylation of Delta9-THCA-A to Delta9-THC was assumed to be complete--which means that no Delta9-THCA-A should be detectable in urine and blood serum of cannabis consumers--we found Delta9-THCA-A in the urine and blood serum samples collected from police controls of drivers suspected for driving under the influence of drugs (DUID). For LC-MS/MS analysis, urine and blood serum samples were prepared by solid-phase extraction. Analysis was performed with a phenylhexyl column using gradient elution with acetonitrile. For detection of Delta9-THCA-A, the mass spectrometer (MS) (SCIEX API 365 triple-quadrupole MS with TurboIonSpray source) was operated in the multiple reaction monitoring (MRM) mode using the following transitions: m/z357 --> 313, m/z357 --> 245 and m/z357 --> 191. Delta9-THCA-A could be detected in the urine and blood serum samples of several cannabis consumers in concentrations of up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The concentration of Delta9-THCA-A was below the Delta9-THC concentration in most serum samples, resulting in molar ratios of Delta9-THCA-A/Delta9-THC of approximately 5.0-18.6%. Only in one case, where a short elapsed time between the last intake and blood sampling is assumed, the molar ratio was 18.6% in the serum. This indicates differences in elimination kinetics, which need to be investigated in detail.

Blood Chemical Analysis↗